What is Phagenyx?
Phagenyx is the developer of the Phagenyx System, a sophisticated neurostimulation device engineered to treat post-stroke dysphagia. By utilizing pharyngeal electrical stimulation, the technology aims to restore the brain's neural control over the swallowing mechanism. This intervention is designed to enhance swallowing safety and efficiency, thereby facilitating faster patient recovery and reducing the duration of hospital stays. The company operates at the intersection of neurology and rehabilitation, providing healthcare providers with a clinically validated tool to improve the quality of life for patients suffering from neurological impairment.
How much funding has Phagenyx raised?
Phagenyx has raised a total of $62.5M across 4 funding rounds:
Series A
$2.3M
Grant
$1.1M
Series B
$17M
Series D
$42M
Series A (2010): $2.3M with participation from Undisclosed
Grant (2012): $1.2M led by Wellcome Trust
Series B (2013): $17M supported by Inventages
Series D (2024): $42M featuring Sectoral Asset Management, British Patient Capital, Northern Gritstone, and EQT Group
Key Investors in Phagenyx
Sectoral Asset Management
An investment advisor specializing in managing equities globally within the healthcare sector, with a strong track record in biotech and private equity strategies.
British Patient Capital
A government-backed entity focused on providing equity finance to innovative, high-growth businesses to drive economic expansion across the UK.
Northern Gritstone
An investment firm founded by leading universities, dedicated to supporting science and technology businesses with a focus on profit with purpose.
What's next for Phagenyx?
With the successful closure of its latest financing round, Phagenyx is well-positioned to scale its commercial operations and expand the reach of its neurostimulation platform. The strategic focus will likely shift toward broader market penetration and the integration of its technology into standard clinical protocols globally. By leveraging the expertise of its diverse investor base, the company is poised to further its mission of transforming dysphagia care through rigorous scientific research and operational excellence. Future milestones will likely involve scaling manufacturing capabilities and pursuing additional regulatory approvals to solidify its market leadership in the neuro-rehabilitation space.
See full Phagenyx company page
